Press Releases
November 16, 2026
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
November 6, 2026
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 5, 2026
IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
October 6, 2026
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 22, 2026
IN8bio to Present at Sidoti Small-Cap Virtual Conference